Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURA3: AZD9291 versus platinum-pemetrexed chemotherapy in EGFR T790M-positive advanced non-small cell lung cancer after prior EGFR-TKI
NL-OMON42148Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2014
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of osimertinib, pemetrexed, carboplatin and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Oct 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON42148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42148.